Top

Published in:

01-12-2009 | Preclinical Study

Meta-analysis of gene expression profiles related to relapse-free survival in 1,079 breast cancer patients

Authors: Balazs Györffy, Reinhold Schäfer

Published in: Breast Cancer Research and Treatment | Issue 3/2009

Abstract

The transcriptome of breast cancers have been extensively screened with microarrays and large sets of genes associated with clinical features have been established. The aim of this study was to validate original gene sets on a large cohort of raw breast cancer microarray data with known clinical follow-up. We recovered 20 publications and matched them to Affymetrix HGU133A annotations. Raw Affymetrix HGU133A microarray data were extracted from GEO and MAS5 normalized. For classifying patients using the selected gene sets, we applied prediction analysis of microarrays and constructed Kaplan–Meier plots. A new classification including all patients was generated using supervised principal components analysis. Seven studies including 1,470 patients were downloaded from GEO. Notably, we uncovered 641 microarrays representing 251 individual tumor specimens among them, which were repeatedly described under independent GEO identifiers. We excluded all redundant data and used the remaining 1,079 samples. Eight of the 20 gene sets were able to predict response at a significance of P < 0.05. The discrimination of good and poor prognosis groups exclusively relying on gene expression data resulted in high significance (P = 1.8E−12). A model including genes fitted by both gene expression and clinical covariates (lymph node status and grade) contains 44 genes and can predict response at P = 9.5E−7. The outcome provides a ranking of the gene lists regarding applicability on an independent dataset. We established a consensus predictor combining the available clinical and gene expression data. The database comprising expression profiles of 1,079 breast cancers can be used to classify individual patients.

Available only for authorised users

Surowiak P, Materna V, Gyorffy B et al (2006) Multivariate analysis of oestrogen receptor alpha, pS2, metallothionein and CD24 expression in invasive breast cancers. Br J Cancer 95:339–346. doi:10.1038/sj.bjc.6603254 CrossRefPubMed

Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874. doi:10.1073/pnas.191367098 CrossRefPubMed

Sotiriou C, Wirapati P, Loi S et al (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98:262–272PubMed

Hu Z, Fan C, Oh DS et al (2006) The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7:96. doi:10.1186/1471-2164-7-96 CrossRefPubMed

Ivshina AV, George J, Senko O et al (2006) Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 66:10292–10301. doi:10.1158/0008-5472.CAN-05-4414 CrossRefPubMed

Petersen OW, Hoyer PE, van DB (1987) Frequency and distribution of estrogen receptor-positive cells in normal, nonlactating human breast tissue. Cancer Res 47:5748–5751PubMed

Kuukasjarvi T, Kononen J, Helin H et al (1996) Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol 14:2584–2589PubMed

Gruvberger S, Ringner M, Chen Y et al (2001) Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 61:5979–5984PubMed

Paik S, Shak S, Tang G et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817–2826. doi:10.1056/NEJMoa041588 CrossRefPubMed

10.

Loi S, Haibe-Kains B, Desmedt C et al (2007) Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 25:1239–1246. doi:10.1200/JCO.2006.07.1522 CrossRefPubMed

11.

Oh DS, Troester MA, Usary J et al (2006) Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol 24:1656–1664. doi:10.1200/JCO.2005.03.2755 CrossRefPubMed

12.

West M, Blanchette C, Dressman H et al (2001) Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci USA 98:11462–11467. doi:10.1073/pnas.201162998 CrossRefPubMed

13.

Ransohoff DF (2004) Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 4:309–314. doi:10.1038/nrc1322 CrossRefPubMed

14.

Buyse M, Loi S, van’t Veer L et al (2006) Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98:1183–1192PubMed

15.

Michiels S, Koscielny S, Hill C (2005) Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 365:488–492. doi:10.1016/S0140-6736(05)17866-0 CrossRefPubMed

16.

Ioannidis JP (2005) Microarrays and molecular research: noise discovery? Lancet 365:454–455PubMed

17.

Naderi A, Teschendorff AE, Barbosa-Morais NL et al (2007) A gene-expression signature to predict survival in breast cancer across independent data sets. Oncogene 26:1507–1516. doi:10.1038/sj.onc.1209920 CrossRefPubMed

18.

Tibshirani R, Hastie T, Narasimhan B et al (2002) Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA 99:6567–6572. doi:10.1073/pnas.082099299 CrossRefPubMed

19.

Bair E, Tibshirani R (2004) Semi-supervised methods to predict patient survival from gene expression data. PLoS Biol 2:E108. doi:10.1371/journal.pbio.0020108 CrossRefPubMed

20.

Lauss M, Kriegner A, Vierlinger K et al (2008) Consensus genes of the literature to predict breast cancer recurrence. Breast Cancer Res Treat 110:235–244. doi:10.1007/s10549-007-9716-3 CrossRefPubMed

21.

Gormley M, Dampier W, Ertel A et al (2007) Prediction potential of candidate biomarker sets identified and validated on gene expression data from multiple datasets. BMC Bioinformatics 8:415. doi:10.1186/1471-2105-8-415 CrossRefPubMed

22.

Ntzani EE, Ioannidis JP (2003) Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment. Lancet 362:1439–1444. doi:10.1016/S0140-6736(03)14686-7 CrossRefPubMed

23.

Simon R, Radmacher MD, Dobbin K et al (2003) Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 95:14–18PubMedCrossRef

24.

Dudoit S, Fridlyand J, Speed T (2002) Comparison of discrimination methods for the classification of tumors using gene expression data. J Am Stat Assoc 97:77–87. doi:10.1198/016214502753479248 CrossRef

25.

Shi L, Reid LH, Jones WD et al (2006) The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol 24:1151–1161. doi:10.1038/nbt1239 CrossRefPubMed

26.

Pawitan Y, Bjohle J, Amler L et al (2005) Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 7:R953–R964. doi:10.1186/bcr1325 CrossRefPubMed

27.

Wang YX, Klijn JGM, Zhang Y et al (2005) Gene-expression pro-files to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365:671–679PubMed

28.

Miller LD, Smeds J, George J et al (2005) An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 102:13550–13555. doi:10.1073/pnas.0506230102 CrossRefPubMed

29.

Desmedt C, Piette F, Loi S et al (2007) Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 13:3207–3214. doi:10.1158/1078-0432.CCR-06-2765 CrossRefPubMed

30.

van ‘t Veer LJ, Dai H, van de Vijver MJ et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530–536. doi:10.1038/415530a CrossRefPubMed

31.

van de Vijver MJ, He YD, van ’t Veer LJ et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999–2009. doi:10.1056/NEJMoa021967 CrossRefPubMed

32.

Sotiriou C, Neo SY, McShane LM et al (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100:10393–10398. doi:10.1073/pnas.1732912100 CrossRefPubMed

33.

Ma XJ, Salunga R, Tuggle JT et al (2003) Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA 100:5974–5979. doi:10.1073/pnas.0931261100 CrossRefPubMed

34.

Ramaswamy S, Ross KN, Lander ES et al (2003) A molecular signature of metastasis in primary solid tumors. Nat Genet 33:49–54. doi:10.1038/ng1060 CrossRefPubMed

35.

Huang E, Cheng SH, Dressman H et al (2003) Gene expression predictors of breast cancer outcomes. Lancet 361:1590–1596. doi:10.1016/S0140-6736(03)13308-9 CrossRefPubMed

36.

Chang JC, Wooten EC, Tsimelzon A et al (2003) Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362:362–369. doi:10.1016/S0140-6736(03)14023-8 CrossRefPubMed

37.

Foekens JA, Atkins D, Zhang Y et al (2006) Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol 24:1665–1671. doi:10.1200/JCO.2005.03.9115 CrossRefPubMed

38.

Paik S, Tang G, Shak S et al (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726–3734. doi:10.1200/JCO.2005.04.7985 CrossRefPubMed

39.

Teschendorff AE, Miremadi A, Pinder SE et al (2007) An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 8:R157. doi:10.1186/gb-2007-8-8-r157 CrossRefPubMed

40.

Korkola JE, Blaveri E, DeVries S et al (2007) Identification of a robust gene signature that predicts breast cancer outcome in independent data sets. BMC Cancer 7:61. doi:10.1186/1471-2407-7-61 CrossRefPubMed

41.

Sorlie T, Tibshirani R, Parker J et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418–8423. doi:10.1073/pnas.0932692100 CrossRefPubMed

Title: Meta-analysis of gene expression profiles related to relapse-free survival in 1,079 breast cancer patients
Authors: Balazs Györffy
Reinhold Schäfer
Publication date: 01-12-2009
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-008-0242-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2009

Reporting of race and ethnicity in breast cancer research: room for improvement

Tamoxifen and ICI 182,780 increase Bcl-2 levels and inhibit growth of breast carcinoma cells by modulating PI3K/AKT, ERK and IGF-1R pathways independent of ERα

Incidence of scalp metastases in breast cancer: a retrospective cohort study in women who were offered scalp cooling

Accuracy of self-reported breast cancer among women undergoing mammography

Therapy related acute myeloid leukemia in breast cancer survivors, a population-based study

Opposite effects of protein kinase C beta1 (PKCβ1) and PKCε in the metastatic potential of a breast cancer murine model

Keynote webinar | Spotlight on antibody–drug conjugates in cancer